Roadmap to an HIV Vaccine

Researchers track the evolution of HIV in a single patient to understand what drives the production of broadly neutralizing antibodies.

Apr 3, 2013
Sabrina Richards

HIV virions.CDC/MAUREEN METCALFE, TOM HODGEBy investigating an African patient’s HIV infection, researchers have traced the development of an antibody that is effective at neutralizing many strains of HIV, according to a study published today (April 3) in Nature. The researchers—who identified the original HIV variant as well as the broadly neutralizing antibody, and pieced together their evolution over the course of infection—hope that a vaccine mimicking this process could encourage the development of such effective HIV-fighting antibodies.

The new research provides “really in-depth information on how a particular type of broadly neutralizing antibody emerges over the course of a natural HIV infection,” said Leonidas Stamatatos, an immunologist at Seattle Biomedical Research Institute who did not participate in the study.

Broadly neutralizing antibodies—able to block many strains of HIV from binding target cells—are notoriously rare: only about 20 percent of HIV-positive people ever generate such antibodies. One of the most attractive neutralizing targets is the HIV envelope protein (Env) that binds T cells, which is present on every variant of HIV. But Env is covered in sugar molecules that often mimic host structures, making it hard for the immune system to distinguish virus from self. In order to avoid an adverse autoimmune reaction, the body produces few B cells whose antibodies can recognize these common structures. One approach to developing an effective HIV vaccine is to stimulate these rare B cells, but because Env’s sequence can vary widely between HIV strains, researchers didn’t know much about the right Env variant for the job.

In order to find an Env that could stimulate an antibody with broadly neutralizing potential, Barton Haynes at Duke University and researchers at the Center for HIV-AIDS Vaccine Immunology (CHAVI) set up eight acute infection clinics in Malawi, South Africa, Tanzania, Uganda, and one in North Carolina, where they could watch antibody and virus develop within weeks of infection.

Haynes and his team found one patient who developed a broadly neutralizing antibody within 3 years of infection. The antibody, dubbed CH103, could block infection of target cells by 55 percent of the HIV virus particles they tested, which expressed a total of 196 different types of Env. Because the team had blood samples from the patient starting 4 weeks after infection, they could isolate the original antibody, CH103’s predecessor, as well as determine the sequence of the original Env protein that first spurred the antibody’s production.

As HIV proteins accrue mutations during an infection, antibodies evolve to increase specificity and adapt to changing targets. Finding the antibody that bound the original Env allowed researchers to identify which mutations conferred broadly neutralizing activity to CH103 and identify mutations in Env that could have contributed to CH103’s development. Haynes and his colleagues hope to recreate the evolution of CH103-like antibodies using the right combination of Env variants in a vaccine.

“The study provides important information on how one might design a rational vaccination strategy,” Dennis Burton, an immunologist at The Scripps Research Institute who did not participate in the study, wrote in an email to The Scientist. “[It’s] a significant leap.”

An effective vaccine will need to elicit more than one type of antibody to block HIV infection, so Haynes and his team are also examining the evolution of broadly neutralizing antibodies and their corresponding HIV proteins in other patients, as well.

Indeed, the bulk of the work is just beginning, said Stamatatos, who noted that the possible combinations of Env “are nearly infinite.” It’s also not clear yet whether the Env mutants should be given together, or provided sequentially in a fashion more akin to a natural infection. Haynes and his colleagues are currently beginning to test both strategies with different Env combinations in macaques and mice engineered to express human antibodies.

H.-X. Liao et al., “Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus,” Nature, doi:10.1038/nature12053, 2013.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!